The Society for
Functional Precision Medicine

Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Virtual Monthly Seminars

Come join us for the first in a series of Virtual Monthly Seminars which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Our first seminar kicks off on Wednesday, July 8th, 2020 at 11:00 AM EST, featuring Caroline Heckman, PhD, Research Director, Institute for Molecular Medicine, Finland, and Gregory Vladimer, PhD, CSO, Allcyte

 Learn More   Register for Seminar

Recent News

June 29, 2020
Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD

Anthony Letai, PhD gives an overview of how BH3 profiling can be used to predict response to therapy. “There is an enormous amount of actionable information that can be obtained from taking the actual cancer cell you’re interested in and subjecting it to a relevant perturbation, that is, exposing it to the actual drugs,” he said. “We nearly completely overlook this in today’s precision medicine approaches, and I think there is enormous unrealized potential in this general approach.”


June 29, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors - Authored by Letai Lab member Patrick Bhola, PhD

“Cancer cells that are cultured for extended periods of time can undergo a variety of changes and may not be representative of the tumor cells that are actually in a mouse or human,” says study first author Patrick Bhola, PhD, of Dana-Farber. “The challenge has been to create a drug-screening technique that shrinks the gap between tumor cells in the body and the cells we do the screening on. The technique we’ve developed helps to accomplish that.” Read Dana Farber’s press release about HT-DBP technology for more information.


June 16, 2020
AACR Virtual Meeting - Dharma Master Jiantai Symposium in Targeted Therapy: Functional Precision Medicine - Techniques, Uses, and Challenges

Because each patient’s cancer is unique, novel approaches are needed to translate clinical and genomic diagnostics to actionable information. While the concept of directly studying a given patient’s tumor cells using functional assays is simple and appealing, the execution is not. Major challenges include technical, analytical, and regulatory, as well as inherent skepticism concerning the use of personalized models for functional testing. Benefits include the ability to functionally interrogate an actual patient’s cancer in unprecedented detail using high throughput assays. This session will present strategies to overcome major challenges and will discuss different applications of functional testing including target identification, preclinical drug and companion diagnostic development, and identification of potentially effective drugs for cancer patients in real time. Attendees will gain an appreciation of how functional testing of patient derived tumor cells can reveal novel insights into cancer biology and accelerate the goals of precision medicine.


March 13, 2020
Humans of Banbury: Interview with Christopher Kemp, PhD

Last month, the Banbury Center held its “CSHL Technology and Education Council: Challenges and Promise in Precision Medicine” meeting (February 18-20). During this time, I was able to meet with Christopher Kemp, Ph.D., and learn about the oncology research he performs and how he’s hoping to make a difference through it. Dr. Kemp, a Full Member at the Fred Hutchinson Cancer Research Center in Seattle, WA, received his doctorate in oncology from the University of Wisconsin–Madison.